Biostem Technologies (BSEM) investor relations material

Strategic transformation and market expansion

• Transitioning from a wound-care focus to a broader regenerative medicine platform with significant exposure to surgical and hospital markets, driven by the acquisition of Neox and Clarix product families from BioTissue.

• Expansion into adjacent surgical markets such as orthopedics, spine, urology, and women's health, each representing billion-dollar opportunities and improving payer mix and revenue quality.

• Diversification of end markets and scaling operational excellence, with a focus on broadening commercial reach and differentiating the product portfolio.

• Integration of BioTissue assets has been successful, aided by experienced management hires and strong retention, supporting early growth.

Technology, clinical validation, and innovation

• Portfolio includes BioRetain, CryoTek, and SteriTek technologies, with six perinatal-derived allograft brands and a robust IP portfolio of 68 issued and 81 pending U.S. patents.

• Over 90 clinical publications and strong clinical data, including randomized controlled trials showing superior healing rates for diabetic foot ulcers and venous leg ulcers.

• Ongoing clinical trials and plans to expand evidence in new indications, including orthopedics and spina bifida, leveraging both internal and acquired clinical programs.

• Product roadmap includes regulatory progress with the 510(k) Catalyze product and continued innovation in preservation technologies.

Commercial strategy and financial outlook

• Expanding direct sales force, leveraging GPO contracts, and using distributors to access hospital systems and rural markets.

• Shift to hospital-based surgical procedures increases exposure to commercial payers, supporting more stable reimbursement and margin expansion.

• Manufacturing transition from BioTissue to internal facilities expected to improve gross margins and profitability.

• Historical BioTissue business generated $29 million in surgical revenue in 2025, with future revenue mix increasingly weighted toward hospital settings.

• Margins expected to be in the 60%+ range during the transition, with potential to rise to the 70–80% range over time as manufacturing is internalized; profitability will require further revenue growth.